Peptide LibraryBy peptide
Research statistics by peptide
How much has been published on each peptide, how much of it is human clinical research, and how many trials are registered. Publication counts cover every year to the cutoff; the share of human clinical research is of classified publications. More publications do not mean stronger evidence. Definitions are on the methodology page.
Automated weekly refresh (not editorially reviewed) · data through November 1, 2026 · version weekly-2026-11-01
Peptides (179)
| Peptide | Publications | Human clinical | RCTs | Trials | Status |
|---|---|---|---|---|---|
| Octreotide | 8,570 | 58.0% | 510 | 253 | FDA-approved |
| Vasoactive Intestinal Peptide (VIP) | 7,195 | 12.2% | 46 | 15 | Research only |
| Secretin | 6,854 | 25.6% | 87 | 37 | FDA-approved |
| Semaglutide | 4,935 | 39.8% | 367 | 649 | FDA-approved |
| Liraglutide | 4,910 | 35.6% | 648 | 456 | FDA-approved |
| Exenatide | 4,357 | 24.0% | 425 | 317 | FDA-approved |
| PACAP-38 | 3,895 | 4.5% | 31 | 13 | Research only |
| Teriparatide | 3,817 | 35.5% | 317 | 162 | FDA-approved |
| Desmopressin | 3,764 | 60.2% | 318 | 103 | FDA-approved |
| Leuprolide | 3,732 | 68.6% | 556 | 380 | FDA-approved |
| Klotho | 3,071 | 35.1% | 49 | 5 | Research only |
| Orexin-A | 2,769 | 15.3% | 24 | 0 | Research only |
| Cosyntropin | 2,701 | 54.5% | 125 | 39 | FDA-approved |
| Tirzepatide | 2,199 | 40.3% | 149 | 252 | FDA-approved |
| LL-37 | 2,182 | 17.2% | 30 | 5 | Research only |
| Goserelin | 1,957 | 73.7% | 429 | 301 | FDA-approved |
| Calcitonin Salmon | 1,768 | 31.3% | 189 | 19 | FDA-approved |
| Bivalirudin | 1,713 | 51.7% | 260 | 69 | FDA-approved |
| Triptorelin | 1,670 | 69.6% | 270 | 200 | FDA-approved |
| Icatibant | 1,450 | 14.6% | 34 | 28 | FDA-approved |
| Lanreotide | 1,278 | 56.0% | 86 | 84 | FDA-approved |
| Eptifibatide | 1,134 | 50.6% | 193 | 30 | FDA-approved |
| Terlipressin | 1,125 | 45.8% | 153 | 95 | FDA-approved |
| Dulaglutide | 1,085 | 53.0% | 168 | 121 | FDA-approved |
| Thymosin β4 (Tβ4) | 968 | 8.5% | 9 | 16 | Research only |
| Enfuvirtide | 806 | 31.9% | 51 | 40 | FDA-approved |
| Thymosin Alpha-1 | 782 | 27.2% | 73 | 59 | Research only |
| Cetrorelix | 759 | 46.1% | 119 | 92 | FDA-approved |
| Pasireotide | 692 | 40.3% | 57 | 84 | FDA-approved |
| Tuftsin | 623 | 4.8% | 2 | 0 | Research only |
| Cerebrolysin | 600 | 36.9% | 68 | 40 | Research only |
| Lixisenatide | 599 | 36.8% | 106 | 66 | FDA-approved |
| Thyrotropin Alfa | 584 | 71.3% | 41 | 26 | FDA-approved |
| Pegvisomant | 549 | 52.1% | 37 | 34 | FDA-approved |
| Atosiban | 545 | 29.4% | 56 | 22 | In clinical trials |
| Thymopentin | 511 | 36.8% | 50 | 9 | Research only |
| Delta Sleep-Inducing Peptide (DSIP) | 499 | 11.1% | 6 | 0 | Research only |
| Humanin | 485 | 14.7% | 5 | 0 | Research only |
| GDF-11 | 457 | 14.7% | 2 | 0 | Research only |
| GHRP-6 | 412 | 21.1% | 17 | 0 | Research only |
| Elamipretide (SS-31) | 409 | 7.4% | 17 | 30 | FDA-approved |
| Carbetocin | 388 | 44.2% | 73 | 96 | In clinical trials |
| Ziconotide | 380 | 22.3% | 5 | 11 | FDA-approved |
| Kisspeptin-10 | 374 | 9.4% | 4 | 17 | Research only |
| Sermorelin | 373 | 23.7% | 19 | 0 | Research only |
| Pramlintide | 365 | 28.1% | 65 | 56 | FDA-approved |
| Nafarelin | 352 | 68.0% | 65 | 10 | FDA-approved |
| Linaclotide | 347 | 30.6% | 50 | 53 | FDA-approved |
| Teduglutide | 339 | 47.3% | 26 | 41 | FDA-approved |
| Thymulin | 325 | 18.9% | 3 | 0 | Research only |
| Degarelix | 308 | 50.3% | 50 | 144 | FDA-approved |
| Oxyntomodulin | 301 | 19.1% | 23 | 4 | Research only |
| Hexarelin (Examorelin) | 289 | 35.2% | 25 | 0 | Research only |
| Ganirelix | 285 | 71.0% | 76 | 67 | FDA-approved |
| Thymalin | 272 | 33.1% | 2 | 0 | Research only |
| Abaloparatide | 271 | 27.2% | 36 | 20 | FDA-approved |
| Melanotan II | 268 | 12.8% | 1 | 1 | Research only |
| Gonadorelin | 255 | 36.9% | 13 | 17 | FDA-approved |
| Pegcetacoplan | 246 | 47.3% | 33 | 35 | FDA-approved |
| Mecasermin | 245 | 35.0% | 22 | 32 | FDA-approved |
| Corticorelin | 232 | 18.7% | 3 | 14 | FDA-approved |
| BPC-157 | 228 | 1.8% | 0 | 3 | Research only |
| MOTS-C | 221 | 27.7% | 4 | 1 | Research only |
| Epitalon | 208 | 9.7% | 6 | 0 | Research only |
| Pralmorelin (GHRP-2) | 202 | 45.0% | 44 | 0 | Research only |
| Kisspeptin-54 (Metastin) | 191 | 31.4% | 11 | 15 | Research only |
| MGF | 187 | 12.9% | 4 | 0 | Research only |
| Semax | 186 | 8.7% | 2 | 0 | Research only |
| Serelaxin | 175 | 21.5% | 30 | 17 | In clinical trials |
| Davunetide | 174 | 8.1% | 9 | 5 | In clinical trials |
| Cortexin | 165 | 54.0% | 17 | 0 | Research only |
| GHK-Cu (Copper Peptide) | 143 | 5.6% | 2 | 1 | Research only |
| Retatrutide | 138 | 14.1% | 12 | 34 | In clinical trials |
| Etelcalcetide | 135 | 53.4% | 23 | 20 | FDA-approved |
| Setmelanotide | 129 | 35.7% | 5 | 26 | FDA-approved |
| Afamelanotide | 125 | 31.5% | 6 | 23 | FDA-approved |
| Histrelin | 124 | 58.2% | 1 | 8 | FDA-approved |
| Tesamorelin | 104 | 37.5% | 30 | 22 | FDA-approved |
| Difelikefalin | 101 | 39.4% | 17 | 28 | FDA-approved |
| Thymogen (Oglufanide) | 101 | 26.1% | 4 | 3 | Research only |
| Vosoritide | 100 | 49.5% | 9 | 18 | FDA-approved |
| Cagrilintide | 96 | 20.0% | 15 | 40 | In clinical trials |
| Angiotensin (1-7) Analog | 90 | 0.0% | 0 | 0 | Research only |
| Plecanatide | 90 | 31.0% | 13 | 15 | FDA-approved |
| Somapacitan | 90 | 54.4% | 31 | 21 | FDA-approved |
| Somatrogon | 74 | 52.7% | 13 | 14 | FDA-approved |
| ARA 290 (Cibinetide) | 73 | 12.3% | 4 | 4 | In clinical trials |
| Survodutide | 71 | 25.4% | 11 | 35 | In clinical trials |
| Selank | 67 | 7.6% | 3 | 0 | Research only |
| Trofinetide | 67 | 47.5% | 9 | 13 | FDA-approved |
| Bremelanotide | 66 | 25.4% | 14 | 10 | FDA-approved |
| KPV | 64 | 0.0% | 0 | 0 | Research only |
| Zilucoplan | 62 | 43.1% | 7 | 19 | FDA-approved |
| Vilon | 59 | 6.8% | 1 | 0 | Research only |
| Cotadutide | 49 | 28.6% | 12 | 24 | In clinical trials |
| Mazdutide | 48 | 31.3% | 12 | 45 | In clinical trials |
| Efpeglenatide | 47 | 29.8% | 13 | 13 | In clinical trials |
| Ipamorelin | 46 | 6.5% | 2 | 2 | Research only |
| Enlicitide | 45 | 15.8% | 5 | 34 | FDA-approved |
| Larazotide | 45 | 15.9% | 5 | 10 | In clinical trials |
| CagriSema | 43 | 23.3% | 8 | 9 | In clinical trials |
| Dasiglucagon | 43 | 38.1% | 14 | 24 | FDA-approved |
| Lonapegsomatropin | 42 | 42.9% | 5 | 12 | FDA-approved |
| Humanin-G (HNG) | 41 | 2.4% | 0 | 0 | Research only |
| Acetyl Hexapeptide-8 | 37 | 35.1% | 6 | 3 | Research only |
| Relamorelin | 34 | 29.4% | 10 | 13 | In clinical trials |
| Motixafortide | 29 | 37.9% | 5 | 22 | FDA-approved |
| GHRP-1 | 28 | 28.6% | 3 | 1 | Research only |
| CJC-1295 | 27 | 11.1% | 1 | 1 | Research only |
| IGF-1 DES | 27 | 0.0% | 0 | 0 | Research only |
| IGF-1 LR3 | 26 | 0.0% | 0 | 0 | Research only |
| PNC-27 | 23 | 4.3% | 0 | 0 | Research only |
| Pinealon | 22 | 22.7% | 0 | 0 | Research only |
| Palmitoyl Pentapeptide-4 | 21 | 19.0% | 3 | 0 | Research only |
| TB-500 (Thymosin Beta-4 fragment) | 21 | 4.8% | 0 | 1 | Research only |
| Livagen | 20 | 0.0% | 0 | 0 | Research only |
| Palmitoyl Tetrapeptide-7 | 20 | 15.8% | 1 | 0 | Research only |
| Ovagen | 19 | 10.5% | 1 | 0 | Research only |
| Amycretin | 16 | 31.3% | 4 | 8 | In clinical trials |
| Cortagen | 15 | 0.0% | 0 | 0 | Research only |
| Ecnoglutide | 15 | 46.7% | 5 | 16 | In clinical trials |
| Rusfertide | 15 | 53.3% | 6 | 10 | FDA-approved |
| SS-20 | 15 | 6.7% | 0 | 0 | Research only |
| AOD-9604 | 14 | 0.0% | 0 | 0 | Research only |
| Bronchogen | 14 | 0.0% | 0 | 1 | Research only |
| FOXO4-DRI | 14 | 0.0% | 0 | 0 | Research only |
| P21 (BDNF-mimetic peptide) | 14 | 0.0% | 0 | 0 | Research only |
| B7-33 | 12 | 0.0% | 0 | 0 | In clinical trials |
| Cardiogen | 12 | 25.0% | 0 | 1 | Research only |
| Pemvidutide | 12 | 33.3% | 3 | 16 | In clinical trials |
| Maridebart cafraglutide | 11 | 18.2% | 2 | 30 | In clinical trials |
| Dihexa | 9 | 0.0% | 0 | 0 | Research only |
| Pancragen | 9 | 11.1% | 0 | 0 | Research only |
| Zinc Thymulin | 9 | 44.4% | 0 | 0 | Research only |
| Petrelintide | 8 | 25.0% | 2 | 12 | In clinical trials |
| ACE-031 | 7 | 28.6% | 2 | 4 | In clinical trials |
| Follistatin-344 | 7 | 14.3% | 0 | 0 | Research only |
| Testagen | 7 | 0.0% | 0 | 1 | Research only |
| Vesugen | 7 | 14.3% | 0 | 0 | Research only |
| Decapeptide-12 | 6 | 80.0% | 1 | 0 | Research only |
| Prostamax | 6 | 0.0% | 0 | 0 | Research only |
| Palmitoyl Tripeptide-1 | 5 | 40.0% | 0 | 0 | Research only |
| Palmitoyl Tripeptide-5 | 4 | 75.0% | 0 | 0 | Research only |
| Adipotide | 3 | 0.0% | 0 | 0 | Research only |
| PTD-DBM | 3 | 0.0% | 0 | 0 | Research only |
| sh-Oligopeptide-1 (Human EGF) | 3 | 66.7% | 0 | 1 | Research only |
| Acetyl Octapeptide-3 | 2 | 100.0% | 0 | 0 | Research only |
| Dipeptide Diaminobutyroyl Benzylamide Diacetate | 2 | 100.0% | 0 | 0 | Research only |
| GH Fragment 176-191 | 2 | 0.0% | 0 | 0 | Research only |
| Palmitoyl Hexapeptide-12 | 2 | 0.0% | 0 | 0 | Research only |
| Acetyl Tetrapeptide-3 | 1 | 100.0% | 1 | 0 | Research only |
| Adamax | 1 | 0.0% | 0 | 0 | Research only |
| AHK-Cu | 1 | 0.0% | 0 | 0 | Research only |
| Chondromix | 1 | 0.0% | 0 | 0 | Research only |
| Chonluten | 1 | 0.0% | 0 | 0 | Research only |
| CJC-1295 (no DAC) / Mod GRF(1-29) | 1 | 0.0% | 0 | 0 | Research only |
| PE-22-28 | 1 | 0.0% | 0 | 0 | Research only |
| PEG-MGF (PEGylated Mechano Growth Factor) | 1 | 0.0% | 0 | 0 | Research only |
| Thymolin | 1 | 100.0% | 0 | 0 | Research only |
| Trifluoroacetyl Tripeptide-2 | 1 | 0.0% | 0 | 0 | Research only |
| VK2735 | 1 | 100.0% | 1 | 8 | In clinical trials |
| Biotinoyl Tripeptide-1 | 0 | — | 0 | 0 | Research only |
| Bonomarlot | 0 | — | 0 | 0 | Research only |
| Cartalax | 0 | — | 0 | 0 | Research only |
| Cerluten | 0 | — | 0 | 0 | Research only |
| Cranoluten | 0 | — | 0 | 0 | Research only |
| Endoluten | 0 | — | 0 | 0 | Research only |
| Libidon | 0 | — | 0 | 0 | Research only |
| Myristoyl Pentapeptide-17 | 0 | — | 0 | 0 | Research only |
| N-Acetyl Selank Amidate | 0 | — | 0 | 0 | Research only |
| N-Acetyl Semax Amidate | 0 | — | 0 | 0 | Research only |
| Pentadeca Arginate | 0 | — | 0 | 0 | Research only |
| Suprefort | 0 | — | 0 | 0 | Research only |
| Svetinorm | 0 | — | 0 | 0 | Research only |
| Testoluten | 0 | — | 0 | 0 | Research only |
| Thyreogen | 0 | — | 0 | 0 | Research only |
| Ventfort | 0 | — | 0 | 0 | Research only |
| Vladonix | 0 | — | 0 | 0 | Research only |
| Zhenoluten | 0 | — | 0 | 0 | Research only |
Other compounds in the library
Not peptides: shown for completeness and left out of every peptide total.
| Peptide | Publications | Human clinical | RCTs | Trials | Status |
|---|---|---|---|---|---|
| AICAR | 1,955 | 2.4% | 10 | 4 | Research only |
| Anamorelin | 148 | 46.6% | 16 | 14 | In clinical trials |
| Orforglipron | 123 | 24.4% | 22 | 53 | FDA-approved |
| Noopept | 86 | 10.6% | 0 | 0 | Research only |
| MK-677 | 81 | 28.8% | 17 | 3 | Research only |
| BAM15 | 60 | 0.0% | 0 | 0 | Research only |
| Tesofensine | 40 | 38.5% | 12 | 13 | In clinical trials |
| Macimorelin | 34 | 50.0% | 7 | 6 | FDA-approved |
| Tabimorelin | 18 | 33.3% | 5 | 0 | In clinical trials |
| ATX-304 | 14 | 7.1% | 0 | 0 | In clinical trials |
| SLU-PP-332 | 9 | 0.0% | 0 | 0 | Research only |
| 5-Amino-1MQ | 3 | 0.0% | 0 | 0 | Research only |
Very large literatures (counts only)
Molecules with literatures too large and general to classify record by record. They are reported as yearly counts, never ranked against the peptides above.